Linked Life Data

20350126

Source:http://linkedlifedata.com/resource/pubmed/id/20350126

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-3-30
pubmed:abstractText
The past decade has seen major advances in our understanding of genomics, with the development of newer and refined technologies. Improvements in the sensitivity and precision of DNA microarrays coupled with the emergence of massively parallel sequencing techniques have redefined how we interrogate the human genome. These tools have facilitated rapid biomarker discovery, uncovered novel targets for therapeutic intervention and enabled mechanistic studies that have helped unravel the mode of drug action. The assessment of drug toxicity based on genomic signatures associated with disease and high-throughput screening for polymorphic interindividual variability in drug responses are procedures that have greatly aided the quality of patient care. The integration of pharmacogenetic approaches for therapeutic monitoring, and health management approaches for advance clinical treatments, will be based on unique patient phenotype profiles and aimed at minimizing adverse drug reactions. In this brief commentary, the evolution and development of key genomics technologies over the past decade is reviewed.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1744-8042
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
481-5
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Advances in pharmacogenomics technologies.
pubmed:affiliation
Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural